Issue link: http://osercommunicationsgroup.uberflip.com/i/365686
C h a i n D ru g s to re D a i l y 5 7 Tu e s d a y, Au g u s t 2 6 , 2 0 1 4 Whether it's the production of medi- cines for pain and attention deficit hyperactivity disorder, the development of products that treat central nervous system conditions or quality imaging products, we are working to make com- plex products simpler, safer and better for patients. Mallinckrodt is a fully inte- grated manufacturer producing the Active Pharmaceutical Ingredient and finished dosage forms. CDD: What would you say makes your company unique? WK: Mallinckrodt is a leader in the man- ufacture and supply of controlled sub- stances. Mallinckrodt Pharmaceuticals is dedicated to providing safe and effective medications for treatment of patients with pain, and is equally committed to working with policy makers, law enforcement and industry to address the complex issues of opioid addiction and abuse. Additionally, Mallinckrodt's phil- anthropic activities strive to advance society in meaningful ways. Our Charitable Giving Program focuses on three strategic areas: Health and Wellness, Science Education and Life Sciences. Under this platform, we fund organizations whose programs increase access to healthcare and wellness servic- es in the community, promote Science, Technology, Engineering, Mathematics (STEM) education in schools and stimu- late economic growth through life sci- ences innovation. We fund programs that specifically benefit the communities where we operate. Mallinckrodt also donates prescription medicines to sup- port global humanitarian needs. When disaster strikes, we work closely with international disaster relief agencies to distribute our products to where they are needed the most. Mallinckrodt ( Cont'd. from p. 1) CDD: Who are your target end-users? WK: In the generic sector we sell to the retail, hospital, government and other pharmacies. We do not call on physi- cians. In the scope of all our products, we use our active pharmaceutical ingredients products in the manufacture of our gener- ic pharmaceuticals and also sell them to other pharmaceutical companies. We market our global medical imaging prod- ucts primarily to physicians, technolo- gists and purchasing administrators at hospitals, imaging centers, cardiology clinics and radiopharmacies. CDD: Where is your current product emphasis? WK: We specialize in highly regulated products such as controlled substances on products with associated REMs. Our organization is dedicated to providing education and tools to support the indus- try in the education and awareness of the many important aspects of controlled substance use and potential for abuse. CDD: Are you introducing any new products? WK: Yes, we intend to launch methylphenidate CD in Q4, 2014. CDD: Tell our readers about your trade show objectives, plans, products, promo- tions, etc. WK: Mallinckrodt is a big sponsor of the NACDS event. Our retail chain cus- tomers are very important to us. We want to support their business through spon- sorships and initiatives that meet their unique needs. For more information, visit booth 315, call 800-325-8888 or go to www.mallinckrodt.com. CAMBER'S GLOBAL RESOURCES PROVIDE ADVANTAGE IN GENERICS MARKETPLACE Ever since its inception, Camber has shown a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Through its parent company, Hetero Drugs of Hyderabad, India, Camber is building on the strengths of vertical integration in dis- covery research, process chemistry, API manufacturing, formulation develop- ment and commercialization. For more than 20 years, research and development has been the foundation of Hetero's phi- losophy of developing cost-effective, high quality and safe medicines to soci- ety. Hetero has a team of more than 400 dedicated scientists working in the areas of Process, Analytical and Discovery Research. Camber's manufacturing partner, Invagen of Hauppauge, N.Y., focuses on a wide range of therapeutic areas, including cardiovascular, anti- infective, CNS, anti-inflammatory, anti- diabetic and anti- depressant. This com- bination of proficien- cies gives Camber the unique ability to con- trol every aspect of the manufacturing process, from API to finished dosage. The company's Global Resources include: facilities and joint ventures in the U.S., India, South America, Spain and the Middle East; total control of the supply chain; more than 400 scientists in API and finished dosage R&D;11 API facilities – six FDA approved; more than 100 DMFs filed; and global presence in over 100 countries. Camber's product strategy is simple – capitalize on its core strengths to deliver maxi- mum profitability to its cus- tomers. It accomplishes this by leveraging a flexible cor- porate structure, providing a broad product line and maintaining an unwavering commitment to quality, value and serv- ice. This philosophy has enabled Camber to grow significantly over the past sever- al years and the company will do every- thing possible to continue to exceed its customer's expectations. For more information about Camber Pharmaceuticals, visit booth 2434, visit www.camberpharma.com or call 732-529-0430. LONGYUN FOODS INTRODUCES SUN-DRIED AND SLOW-ROASTED TOMATOES WITH GOLDEN LAKE Grown in the Himalayan Mountains, the tomatoes used by Longyun Foods mature in optimal conditions. In one of the last pris- tine corners of the Earth, Longyun tomatoes are cultivated with snow water, mountain air and radiant sun – leading to products packed with vitamins as well as lycopene. Longyun's tomatoes are processed in sterile, state-of-the-art facilities where industry and government agents inspect production. Every step is meticulously car- ried out to ensure only the finest products reach consumers. All of Longyun Foods' products are processed in accordance with GMP standards and HACCP plan, and the manufacturer is certified by ISO22000, BRC and Kosher organizations. After achieving success in European and Japanese markets, Longyun Foods now brings its products to American mar- kets through collaboration with Golden Lake. Golden Lake is an American brand known for food products that boast great taste, freshness and affordability. Golden Lake has formed partner- ships with trusted companies such as Western Beef, Key Foods and Shop-Rite. To ensure only the best reaches its cus- tomers, Golden Lake sends out samples for ingredient screening and bio-analysis to guarantee consistent high quality. For more information on Longyun, email sales@longyunfoods.com or visit www.longyunfoods.com. For more informa- tion about Golden Lake/Amerihua Produce, email info@amerihuaproduce.com or visit www.amerihuaproduce.com. ALAMEDA HEALTH SYSTEM NAMES KINZI RICHHOLT CHIEF NURSE EXECUTIVE Alameda Health System (AHS) has announced that Kinzi Richholt has been named Chief Nurse Executive. A veteran of Bay Area health care with more than 25 years of experience, Ms. Richholt joined AHS in February 2014 as the interim Chief Nurse Executive and will continue overseeing nursing services and operations throughout the network in this permanent appointment. "Kinzi's skill set combines a passion for nursing with a keen strategic vision, both of which are vital at a health care sys- tem committed to providing a family and patient centered system of care for all," said Wright L. Lassiter, III, Chief Executive Officer of AHS. "Under Kinzi's stellar guidance, AHS nurses continue to fulfill this mission for excellence." Ms. Richholt most recently served as a consultant for Kaiser Permanente Medical Center in Antioch, Calif. At Kaiser, she implemented strategic initia- tives to improve care experience and sig- nificantly raised Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores. She also con- sulted for Rady Children's Hospital in San Diego, Calif., where she mentored new nursing leaders, developed care experi- ence plans and addressed productivity. She was also Chief, System Operations and Management Support Services at Washington Hospital Healthcare System in Fremont, Calif., where she led cardiovascular and periop- erative services, pharmacy, materials management, and food and nutrition services. Prior to that role, she held sev- eral positions at St. Rose Hospital in Hayward, Calif. including Senior Vice President, Vice President of Patient Care Services/Chief Nurse Executive, and Clinical Nurse Manager of Perinatal Services. Her accomplishments at St. Rose Hospital include creating a "Partners-in-Practice" delivery care sys- tem in collaboration with the Chief of the Medical Staff, and managing all opera- tions. Ms. Richholt received a Bachelor's Degree in Nursing from Holy Names College in Oakland, and a Master's Degree in Nursing from the University of California, San Francisco. About Alameda Health System (AHS) Alameda Health System, a major pub- lic health care provider headquartered in Oakland, California, is recognized as a world-class patient and family cen- tered system of care with more than 4,500 employees, 1,000 physicians and 480 volunteers. Their facilities include Highland Hospital, a major regional trauma center and teaching hospital; Alameda Hospital, an acute care facili- ty providing emergency, in-patient and outpatient services in Alameda; San Leandro Hospital, which provides emergency and in-patient hospital care services; John George Psychiatric Hospital, an acute and emergency care facility in San Leandro; Fairmont Hospital, an acute rehabilitation hospi- tal and skilled nursing facility, also in San Leandro; and four ambulatory wellness centers in Oakland as well as in Newark and Hayward.